Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bimosiamose. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELP known ✓ | P16109 | 2/20 | 1.00 |
| ▸ | SELPLG | Q14242 | 1/20 | 1.00 |
| ▸ | PPARG | P37231 | 2/20 | 0.54 |
| ▸ | PPARD | Q03181 | 2/20 | 0.54 |
| ▸ | PPARA | Q07869 | 2/20 | 0.54 |
| ▸ | SLC28A3 | Q9HAS3 | 2/20 | 0.47 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bimosiamose SCHEMBL14970212 | 1.00 | SELP (1.00) | SELPSELPLGPPARGPPARDPPARA | |
| Bimosiamose SCHEMBL14015902 | 1.00 | SELP (1.00) | SELPSELPLGPPARGPPARDPPARA | |
| Bimosiamose SCHEMBL29367817 | 1.00 | SELP (1.00) | SELPSELPLGPPARGPPARDPPARA | |
| Bimosiamose SCHEMBL26341832 | 1.00 | SELP (1.00) | SELPSELPLGPPARGPPARDPPARA | |
| Bimosiamose SCHEMBL29372538 | 1.00 | SELP (1.00) | SELPSELPLGPPARGPPARDPPARA | |
| SCHEMBL7614341 | 1.00 | SELP (1.00) | SELPSELPLGPPARGPPARDPPARA | |
| Bimosiamose SCHEMBL2529148 | 1.00 | SELP (1.00) | SELPSELPLGPPARGPPARDPPARA | |
| SCHEMBL7620761 | 1.00 | SELP (1.00) | SELPSELPLGPPARGPPARDPPARA | |
| Bimosiamose SCHEMBL2528669 | 0.99 | SELP (0.98) | SELPSELPLGPPARGPPARDPPARA | |
| SCHEMBL8205205 | 0.99 | SELP (0.98) | SELPSELPLGPPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2607368-A1 | Crystalline forms of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-alpha-D-mannopyranosyl-oxy)-phenyl] hexane | Revotar Biopharmaceuticals AG (DE) | 2013-06-26 | — | — | EP | disclosed |
| EP-2089407-B1 | CRYSTALLINE FORMS OF 1,6-BIS [3-(3-CARBOXYMETHYLPHENYL)-4-(2-ALPHA-D-MANNOPYRANOSYL-OXY)-PHENYL]HEXANE | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2013-05-22 | — | — | EP | disclosed |
| CN-103002951-A | Process for the preparation of new compound | REVOTAR BIOPHARMACEUTICALS AG | 2013-03-27 | — | — | CN | disclosed |
| CN-101541821-B | Crystalline forms of 1,6-bis [3-(3-carboxymethylphenyl)-4-(2-alpha-D-mannopyranosyl-oxy)-phenyl] hexane | REVOTAR BIOPHARMACEUTICALS AG | 2013-03-20 | — | — | CN | disclosed |
| CN-101541821-B | Crystalline forms of 1,6-bis [3-(3-carboxymethylphenyl)-4-(2-alpha-D-mannopyranosyl-oxy)-phenyl] hexane | REVOTAR BIOPHARMACEUTICALS AG | 2013-03-20 | — | — | CN | disclosed |
| WO-2011138365-A1 | PROCESS FOR THE PREPARATION OF BIMOSIAMOSE | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2011-11-10 | — | — | WO | disclosed |
| US-20110257114-A1 | CRYSTALLINE FORMS OF 1,6-BIS [3-(3-CARBOXYMETHYLPHENYL)-4-(2-ALPHA-D-MANNOPYRANOSYL-OXY)-PHENYL] HEXANE | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2011-10-20 | — | — | US | disclosed |
| US-20110257114-A1 | CRYSTALLINE FORMS OF 1,6-BIS [3-(3-CARBOXYMETHYLPHENYL)-4-(2-ALPHA-D-MANNOPYRANOSYL-OXY)-PHENYL] HEXANE | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2011-10-20 | — | — | US | disclosed |
| US-8039601-B1 | Crystalline forms of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-α-D-mannopyranosyloxy)-phenyl] hexane | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2011-10-18 | — | — | US | disclosed |
| US-8039601-B1 | Crystalline forms of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-α-D-mannopyranosyloxy)-phenyl] hexane | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2011-10-18 | — | — | US | disclosed |
| US-20100298245-A1 | Pharmaceutical Composition for the Treatment of IL-8 mediated diseases | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2010-11-25 | — | — | US | disclosed |
| US-20100144654-A1 | Crystalline forms of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-alpha-D-mannopyranosyl-oxy)-phenyl] hexane | REVOTAR BIOPHAMACEUTICALS AG (DE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144654-A1 | Crystalline forms of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-alpha-D-mannopyranosyl-oxy)-phenyl] hexane | REVOTAR BIOPHAMACEUTICALS AG (DE) | 2010-06-10 | — | — | US | disclosed |
| US-20100093653-A1 | Use of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-alpha-D-mannopyranosyl-oxy)-phenyl] hexane for the preparation of cosmetic compositions | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093653-A1 | Use of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-alpha-D-mannopyranosyl-oxy)-phenyl] hexane for the preparation of cosmetic compositions | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2010-04-15 | — | — | US | disclosed |
| CN-101541821-A | 1, crystalline form of 6-bis [3-(3-carboxymethylphenyl)-4-(2-α-D-mannopyranosyl-oxy)-phenyl] ethane | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2009-09-23 | — | — | CN | disclosed |
| EP-1903049-A1 | Crystalline forms of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-alpha -D-mannopyranosyloxy)-phenyl] hexane | Revotar Biopharmaceuticals AG (DE) | 2008-03-26 | — | — | EP | disclosed |
| WO-2008028966-A1 | CRYSTALLINE FORMS OF 1,6-BIS [3-(3-CARBOXYMETHYLPHENYL)-4-(2-ALPHA-D-MANNOPYRANOSYL-OXY)-PHENYL] HEXANE | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2008-03-13 | — | — | WO | disclosed |
| WO-2008028950-A1 | USE OF 1,6-BIS [3-(3-CARBOXYMETHYLPHENYL)-4-(2-ALPHA-D-MANNOPYRANOSYL-OXY)-PHENYL] HEXANE FOR THE PREPARATION OF COSMETIC COMPOSITIONS | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2008-03-13 | — | — | WO | disclosed |
| EP-1897533-A1 | Use of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-alpha -D-mannopyranosyl-oxy)-phenyl] hexane for the preparation of cosmetic compositions | Revotar Biopharmaceuticals AG (DE) | 2008-03-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257114-A1 | CRYSTALLINE FORMS OF 1,6-BIS [3-(3-CARBOXYMETHYLPHENYL)-4-(2-ALPHA-D-MANNOPYRANOSYL-OXY)-PHENYL] HEXANE | DPM1, ALG1, CHIT1 | SELP 562/4885SELPLG 779/4885PPARG 2057/4885 |
| US-20100298245-A1 | Pharmaceutical Composition for the Treatment of IL-8 mediated diseases | CXCL8, IL18, IL1B | SELP 191/4885SELPLG 303/4885PPARG 517/4885 |
| US-20100093653-A1 | Use of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-alpha-D-mannopyranosyl-oxy)-phenyl] hexane for the preparation of cosmetic compositions | DPM1, DEGS1, GLA | SELP 1755/4885SELPLG 2678/4885PPARG 663/4885 |
| US-20100144654-A1 | Crystalline forms of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-alpha-D-mannopyranosyl-oxy)-phenyl] hexane | DPM1, ALG1, CHIT1 | SELP 562/4885SELPLG 779/4885PPARG 2057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.